Buprenorphine: Effects on Pain and Substitution

Buprenorphine (brand names Temgesic, Subutex, Suboxone, Norspan, Transtec, and generics) is a partial agonist at the μ opioid receptor and an antagonist at the κ receptor. In Germany, buprenorphine is approved both for pain management and for substitution treatment of opioid dependence. Compared to full agonists such as morphine, oxycodone, or fentanyl, buprenorphine offers a more favorable safety profile with a so-called ceiling effect for respiratory depression. This makes buprenorphine attractive in ambulatory substitution medicine and for patients with comorbidities.

The transdermal form (patch) has become established in the treatment of chronic pain because drug levels are maintained evenly over several days. Sublingual tablets and films dominate substitution treatment. The combination with naloxone (Suboxone) reduces abuse potential: with sublingual administration, naloxone is only minimally absorbed, whereas with intravenous abuse it acts as an opioid antagonist and reduces the effect. This mechanism is an example of a pharmacological safety strategy.

Mechanism of Action

Buprenorphine binds with high affinity to the μ opioid receptor but dissociates slowly. As a partial agonist, it produces a submaximal activation. Even with increasing doses, analgesic and respiratory depressive effects reach a plateau. This ceiling effect is therapeutically valuable because it significantly reduces the risk of fatal respiratory depression. At the κ receptor, buprenorphine acts as an antagonist, which in animal models has been associated with antidepressant and mood-stabilizing effects.

The high receptor affinity also means that buprenorphine can displace already bound full agonists. Those who have used full μ agonists shortly before buprenorphine administration may experience a precipitated withdrawal syndrome with sweating, nausea, tremor, pain, anxiety, and diarrhea. This phenomenon is clinically important and is why switching to buprenorphine follows clearly defined protocols.

The half-life of buprenorphine is very long (24 to 60 hours), and the duration of action at the receptor is further prolonged by slow dissociation. This allows once-daily or even every-two-days dosing in substitution medicine. Metabolism is predominantly hepatic via CYP3A4 to norbuprenorphine and glucuronides, which are subsequently excreted in the bile. Renal burden is low.

Areas of Use

• Moderate to severe chronic pain, especially in patients with impaired renal function or elderly people, transdermal patch well controllable
• Postoperative pain management to a lesser extent, often sublingual or intravenous
• Cancer pain, patch and sublingual tablet as part of WHO step three
• Substitution therapy for opioid dependence sublingual, with or without naloxone combination
• Adjunctive in chronic pain disorder with addiction medicine comorbidity, individualized treatment planning

In emergencies (severe postoperative pain, polytrauma), full agonists are often easier to control. Buprenorphine is not first choice if high-dose acute therapy or rapid switching to another opioid agonist is planned.

Dosage and Administration

Pain management sublingual: 0.2 to 0.4 mg every six to eight hours, maximum dose generally below 2 mg per day, individually higher in specialized pain medicine.

Transdermal patch (Norspan): 5 to 20 µg per hour, changed every seven days. Higher dose patch (Transtec): 35 to 70 µg per hour, changed every three to four days. Do not cut patches, do not place directly on heaters or heat sources because uncontrolled drug release threatens.

Substitution treatment: Begin with 2 to 4 mg sublingual, increase in 2 to 4 mg increments on the first day, maintenance dose usually 8 to 24 mg per day. Sublingual tablets or films dissolve slowly under the tongue, swallowing or chewing significantly reduces bioavailability.

Renal insufficiency: Buprenorphine is one of the preferred opioids in impaired renal function since it is metabolized predominantly hepatically. Hepatic insufficiency: Caution with severe functional impairment, dose reduction required. Elderly patients: Reduce starting dose, slow titration.

Side Effects

Very common: Nausea, vomiting, constipation, fatigue, dizziness, headache, sweating.

Common: Dry mouth, sleep disorders, loss of appetite, local skin reactions under the patch, sublingual oral mucosa irritation, loss of libido, hypotension.

Uncommon to rare: Respiratory depression especially in combination with other CNS depressants, bradycardia, allergic skin reactions, hallucinations, seizures, elevated liver enzymes.

Substitution-specific: Precipitated withdrawal with too early administration after heroin or other full agonists, therefore dose escalation with defined minimum interval from last opioid dose.

Long-term therapy: Hypogonadism with reduced testosterone, menstrual cycle disorders, depressive mood, hyperalgesia. Regular monitoring is advisable.

Drug Interactions

• Benzodiazepines, Z-substances, alcohol: Enhanced respiratory depression and sedation, clearly increased mortality risk in studies, avoid combination if possible or monitor closely.
• CYP3A4 inhibitors (itraconazole, ketoconazole, erythromycin, clarithromycin, ritonavir, grapefruit juice): Increased levels and enhanced effects.
• CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John's wort): Reduced levels, loss of effect possible.
• Naltrexone, naloxone (except combination product): Triggering severe withdrawal.
• Full μ agonists (morphine, oxycodone, fentanyl, methadone): Reduced effect of agonists during ongoing buprenorphine therapy, precipitated withdrawal with switching without pause.
• SSRI, SNRI, MAO inhibitors, tricyclics: Theoretical risk of serotonin syndrome, caution with higher dose combinations.
• QT-prolonging agents: Possible additive effect at high dose, consider ECG monitoring.

Special Precautions

Pregnancy: Buprenorphine is considered equivalent to or slightly better tolerated than methadone for the newborn. Substitution therapy should be continued in pregnancy, withdrawal attempts are potentially dangerous. Birth and postpartum period are ideally managed at a specialized clinic. Breastfeeding: Very low transfer into breast milk, breastfeeding under substitution generally possible, consult with addiction medicine and pediatrics.

Children and adolescents: Pain management under specialized pediatrics, substitution only according to age and indication per guideline.

Respiratory diseases: Caution with severe COPD, sleep apnea, or reduced respiratory reserve. The ceiling effect does not protect against respiratory depression when sedation is combined with benzodiazepines or alcohol.

Driving ability: Particularly at the beginning and with dose changes, reaction capacity may be impaired. No driving during titration, later assess individually.

Patch precautions: Change skin site, do not cut, remove before MRI (some patches contain metallic components), fold patch after use and dispose safely because residual amounts are sufficient to cause poisoning in children or animals.

You Might Also Be Interested In

• Methadone, full μ agonist in substitution and pain management
• Morphine, gold standard of strong opioids
• Oxycodone, semi-synthetic strong opioid
• Tapentadol, μ agonist with additional noradrenaline reuptake inhibition
• Sufentanil, highly potent opioid in anesthesia

Frequently Asked Questions

Sources

• Gelbe Liste, Buprenorphine active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for pain management and substitution treatment
• EMA, European Medicines Agency